These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 22890270)

  • 1. Profiling alterations in platelets induced by Amotosalen/UVA pathogen reduction and gamma irradiation--a LC-ESI-MS/MS-based proteomics approach.
    Thiele T; Sablewski A; Iuga C; Bakchoul T; Bente A; Görg S; Völker U; Greinacher A; Steil L
    Blood Transfus; 2012 May; 10 Suppl 2(Suppl 2):s63-70. PubMed ID: 22890270
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pathogen inactivation with amotosalen plus UVA illumination minimally impacts microRNA expression in platelets during storage under standard blood banking conditions.
    Arnason NA; Johannson F; Landrö R; Hardarsson B; Irsch J; Gudmundsson S; Rolfsson O; Sigurjonsson OE
    Transfusion; 2019 Dec; 59(12):3727-3735. PubMed ID: 31674051
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biochemical and functional characteristics of stored (double-dose) buffy-coat platelet concentrates treated with amotosalen and a prototype UVA light-emitting diode illuminator.
    Brouard N; Pissenem-Rudwill F; Mouriaux C; Haas D; Galvanin A; Kientz D; Mangin PH; Isola H; Hechler B
    Transfusion; 2023 Oct; 63(10):1937-1950. PubMed ID: 37615493
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inactivation of yellow fever virus with amotosalen and ultraviolet A light pathogen-reduction technology.
    Girard YA; Santa Maria F; Lanteri MC
    Transfusion; 2020 Mar; 60(3):622-627. PubMed ID: 31957887
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patient outcomes and amotosalen/UVA-treated platelet utilization in massively transfused patients.
    Nussbaumer W; Amato M; Schennach H; Astl M; Chen CY; Lin JS; Corash L; Benjamin RJ
    Vox Sang; 2017 Apr; 112(3):249-256. PubMed ID: 28198023
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pathogen inactivation of double-dose buffy-coat platelet concentrates photochemically treated with amotosalen and UVA light: preservation of in vitro function.
    Sandgren P; Diedrich B
    Vox Sang; 2015 May; 108(4):340-9. PubMed ID: 25557354
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inactivation of a broad spectrum of viruses and parasites by photochemical treatment of plasma and platelets using amotosalen and ultraviolet A light.
    Lanteri MC; Santa-Maria F; Laughhunn A; Girard YA; Picard-Maureau M; Payrat JM; Irsch J; Stassinopoulos A; Bringmann P
    Transfusion; 2020 Jun; 60(6):1319-1331. PubMed ID: 32333396
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevention of transfusion-associated graft-versus-host disease with pathogen-reduced platelets with amotosalen and ultraviolet A light: a review.
    Cid J
    Vox Sang; 2017 Oct; 112(7):607-613. PubMed ID: 28833219
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimized processing for pathogen inactivation of double-dose buffy-coat platelet concentrates: maintained in vitro quality over 7-day storage.
    Ohlsson S; Diedrich B; Uhlin M; Sandgren P
    Vox Sang; 2018 Oct; 113(7):611-621. PubMed ID: 30156292
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficient inactivation of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) in human apheresis platelet concentrates with amotosalen and ultraviolet A light.
    Hindawi SI; El-Kafrawy SA; Hassan AM; Badawi MA; Bayoumi MM; Almalki AA; Zowawi HM; Tolah AM; Alandijany TA; Abunada Q; Picard-Maureau M; Damanhouri GA; Azhar EI
    Transfus Clin Biol; 2022 Feb; 29(1):31-36. PubMed ID: 34411748
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pathogen reduction with amotosalen/UVA reduces platelet refractoriness in a dog platelet transfusion model.
    Slichter SJ; Bailey SL; Gettinger I; Pellham E; Christoffel T; Castro G; Green JM; Stassinopoulos A
    Vox Sang; 2019 Aug; 114(6):595-604. PubMed ID: 31297836
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Amotosalen-HCl-UVA pathogen reduction does not alter poststorage metabolism of soluble CD40 ligand, Ox40 ligand and interkeukin-27, the cytokines that generally associate with serious adverse events.
    Hamzeh-Cognasse H; Laradi S; Osselaer JC; Cognasse F; Garraud O
    Vox Sang; 2015 Feb; 108(2):205-7. PubMed ID: 25334045
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolomics study of platelet concentrates photochemically treated with amotosalen and UVA light for pathogen inactivation.
    Jóhannsson F; Árnason NÁ; Landrö R; Guðmundsson S; Sigurjonsson ÓE; Rolfsson Ó
    Transfusion; 2020 Feb; 60(2):367-377. PubMed ID: 31802514
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Amotosalen and ultraviolet A light efficiently inactivate MERS-coronavirus in human platelet concentrates.
    Hashem AM; Hassan AM; Tolah AM; Alsaadi MA; Abunada Q; Damanhouri GA; El-Kafrawy SA; Picard-Maureau M; Azhar EI; Hindawi SI
    Transfus Med; 2019 Dec; 29(6):434-441. PubMed ID: 31696565
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The clinical and biological impact of new pathogen inactivation technologies on platelet concentrates.
    Kaiser-Guignard J; Canellini G; Lion N; Abonnenc M; Osselaer JC; Tissot JD
    Blood Rev; 2014 Nov; 28(6):235-41. PubMed ID: 25192602
    [TBL] [Abstract][Full Text] [Related]  

  • 16. LC-MS/MS analysis and comparison of oxidative damages on peptides induced by pathogen reduction technologies for platelets.
    Prudent M; Sonego G; Abonnenc M; Tissot JD; Lion N
    J Am Soc Mass Spectrom; 2014 Apr; 25(4):651-61. PubMed ID: 24470194
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cryopreservation of buffy coat-derived platelet concentrates photochemically treated with amotosalen and UVA light.
    Meinke S; Wikman A; Gryfelt G; Hultenby K; Uhlin M; Höglund P; Sandgren P
    Transfusion; 2018 Nov; 58(11):2657-2668. PubMed ID: 30281156
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Amotosalen/ultraviolet A pathogen inactivation technology reduces platelet activatability, induces apoptosis and accelerates clearance.
    Stivala S; Gobbato S; Infanti L; Reiner MF; Bonetti N; Meyer SC; Camici GG; Lüscher TF; Buser A; Beer JH
    Haematologica; 2017 Oct; 102(10):1650-1660. PubMed ID: 28729303
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Generation of procoagulant collagen- and thrombin-activated platelets in platelet concentrates derived from buffy coat: the role of processing, pathogen inactivation, and storage.
    Bertaggia Calderara D; Crettaz D; Aliotta A; Barelli S; Tissot JD; Prudent M; Alberio L
    Transfusion; 2018 Oct; 58(10):2395-2406. PubMed ID: 30229925
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical impact of amotosalen-ultraviolet A pathogen-inactivated platelets stored for up to 7 days.
    Infanti L; Holbro A; Passweg J; Bolliger D; Tsakiris DA; Merki R; Plattner A; Tappe D; Irsch J; Lin JS; Corash L; Benjamin RJ; Buser A
    Transfusion; 2019 Nov; 59(11):3350-3361. PubMed ID: 31574181
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.